About: Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 July 2005

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2005 (fr) наукова стаття, опублікована в липні 2005 (uk) artículu científicu espublizáu en xunetu de 2005 (ast) scientific article published on 01 July 2005 (en)
publication date	wds:Q80405355-0C8318C9-5789-4E0B-8352-6C4E64A9C432
publication date	2005-07-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q80405355-0C64BDA1-E12E-48D0-AE57-CE8F0A5AF875 wds:Q80405355-31603B49-3D16-4826-8FD3-C294D6C9F5DF wds:Q80405355-38FA3698-701E-4D0B-A70C-6CA3B7F7128D wds:Q80405355-4171A122-4F24-4EF2-B1FC-A27244FDD506 wds:Q80405355-4C9FA8DA-1E6A-4C3A-91FB-01E2632417DB wds:Q80405355-55A60D4A-58E1-4D50-9B78-429BC01471EB wds:Q80405355-665F3BAA-0245-43CB-BE2A-6622B5D801DA wds:Q80405355-69D3176F-3433-4F36-B992-3E5C3CDB91F0 wds:Q80405355-7811AB3A-0493-4588-80B4-B5A5CD23C2E2 wds:Q80405355-8FE5317F-8269-420D-BB81-041AA2765B78 wds:Q80405355-97A6B9E8-7A43-4FBE-AE7B-FA579B61F8B8 wds:Q80405355-B2658755-0080-4F9D-8858-25EFD93981DA wds:Q80405355-FD694A95-DD13-459D-86A3-56453384B5D8
author name string	Andreas Engert Franck Morschhauser Volker Diehl Thomas Fischer Peter Borchmann Andrew Raubitschek Harald Schicha Markus Dietlein Hinrich Hansen Wolfgang Eschner Jan Oliver Staak Klaus Schomaecker Roland Schnell
rdfs:label	Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody (en) Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody (nl)
skos:prefLabel	Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody (en) Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody (nl)
name	Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody (en) Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody (nl)
title	wds:Q80405355-2D480436-F032-4C68-9CCA-CF60FB706D8D
title	Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody (en)
page(s)	wds:Q80405355-8FA86E53-8FE1-4871-B8AB-93477B012E5B
page(s)	4669-4678
instance of	wds:Q80405355-974E1BA8-32FF-434D-9219-9D533082F2FE
instance of	scholarly article
main subject	wds:Q80405355-BF987FAF-B0AA-4A8D-88E7-19D1AE9B1186
main subject	monoclonal antibody
PubMed ID	wds:Q80405355-E1D796F3-A957-4C4A-BA87-98BF00E54E35
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16034043
PubMed ID	16034043
published in	wds:Q80405355-CB4127CF-1120-4789-B613-3414897DF59E
published in	Journal of Clinical Oncology
issue	wds:Q80405355-7CDD0FCB-A66D-4B70-9A84-AA35C323B00B
volume	wds:Q80405355-779539FD-1E88-4F8D-BEAA-C489EA0FBA9F
issue	21
volume	23
DOI	wds:Q80405355-FFC0A8EE-15DD-4558-8978-9EC8856AC371
DOI	http://dx.doi.org/10.1200/JCO.2005.09.098
DOI	10.1200/JCO.2005.09.098
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q80405355
is cites work of	Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma Role of CD30 targeting in malignant lymphoma Anti-CD30 Antibodies for Hodgkin lymphoma. Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options. Does rituximab have a place in treating classic hodgkin lymphoma? Constitutive overexpression of a novel 21 kDa protein by Hodgkin lymphoma and aggressive non-Hodgkin lymphomas. Ongoing development of monoclonal antibodies and antibody drug-conjugates in lymphoma Current approaches to the management of pediatric Hodgkin lymphoma Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin. Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. Clinical development of CAR T cell therapy in China: 2020 update The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients Immunotherapies for Hodgkin's lymphoma 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B). Targeting CD30 in anaplastic large cell lymphoma CD30-positive malignant lymphomas: time for a change of management? Current and future aspects of nuclear molecular therapies: a model of theranostics. Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma? Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond. Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma
is cites work of	wds:Q37238152-876B849A-DDDB-44C6-96E2-FD3E8941B0E4 wds:Q37758445-8ACF606B-5CAA-4F5D-AFD2-D50F3BFC9CC2 wds:Q63633986-037A00CE-EC7E-4CDB-80AD-ACC90D89DA97 wds:Q100395396-94B5279C-0AB8-499C-8343-78885CAFFAA2 wds:Q39310790-5A23BD26-75AB-4B61-90C6-B60859862FA8 wds:Q37706528-C323A0D5-0AA6-4E04-9F4F-D5CB85B75F71 wds:Q43065863-11FC6886-8439-4EEA-970A-2259D7C6F8DF wds:Q51652256-68A9C103-869E-463D-BD9E-1C790A9D0547 wds:Q36207446-022F553C-4DC3-4D53-B8A6-8B96A2370B5D wds:Q34240314-02940C52-48F9-4983-BE3A-DB4F9E65028A wds:Q38191191-E5FBF600-3490-4CE1-B091-953A82F7013F

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software